David Krempa Sells 19,679 Shares of Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 19,679 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13. Following the transaction, the insider owned 25,249 shares in the company, valued at approximately $794,586.03. This trade represents a 43.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83.
• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total transaction of $1,181,630.76.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON opened at $31.86 on Friday. Eton Pharmaceuticals, Inc. has a fifty-two week low of $13.09 and a fifty-two week high of $35.66. The business has a 50-day moving average of $26.85 and a two-hundred day moving average of $20.14. The stock has a market capitalization of $872.65 million, a P/E ratio of -455.08 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. On average, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Opaleye Management Inc. increased its stake in shares of Eton Pharmaceuticals by 0.3% in the second quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock worth $40,755,000 after purchasing an additional 7,930 shares during the period. EcoR1 Capital LLC increased its stake in shares of Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after purchasing an additional 141,394 shares during the period. Vanguard Group Inc. increased its stake in shares of Eton Pharmaceuticals by 2.4% in the third quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after purchasing an additional 31,942 shares during the period. State Street Corp increased its stake in shares of Eton Pharmaceuticals by 14.5% in the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock worth $8,488,000 after purchasing an additional 63,480 shares during the period. Finally, Cannell Capital LLC increased its stake in shares of Eton Pharmaceuticals by 17.3% in the third quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock worth $9,896,000 after purchasing an additional 67,230 shares during the period. 27.86% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ETON shares. B. Riley Financial boosted their price target on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Craig Hallum boosted their price target on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. HC Wainwright boosted their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eton Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $41.00.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.